Worth reading
48Recurring
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
12.8
Year-on-year change in revenue (%)Wording
Conditional
How definitive the wording is.Results for this period
Full year2021年4月1日〜2022年3月31日ConsolidatedIFRSNet Sales137,484¥ millionYear on year +12.8%Progress 102.6%
Operating profit32,948¥ millionYear on year +21.1%Progress 122.0%
Ordinary income33,301¥ millionYear on year +20.6%Progress 121.1%
Net income attributable to owners of the parent24,986¥ millionYear on year +27.9%Progress 116.2%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share370.97円
Operating Margin24.0%
Financial position at period-end
Total assets219,943¥ million
of which net assets 180,886 ¥ millionEquity ratio 82.1%vs. prior year-end +2.7pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+21,316
Investment-10,037
Financials-8,407
Net change+2,872
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥60,566 million
Segment revenuePharmaceuticals Business ¥120,650 million, Functional Foods Business ¥16,834 million
Segment profitPharmaceuticals Business ¥32,244 million, Functional Foods Business ¥529 million
Regional sales¥94,367 million, ¥29,989 million, ¥29,982 million, ¥13,128 million, ¥137,484 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥134,000 million (YoY -2.5%)
Operating profit¥27,000 million (YoY -18.1%)
Ordinary income¥27,500 million (YoY -17.4%)
Net income¥21,500 million (YoY -14.0%)
Annual Dividend Forecast¥110 → ¥112（+1.8%）
Payout ratio29.7%（2023年3月期予想35.1%）
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 Not disclosed
Changes in the scope of consolidationNew Number of companies 1 / Company name 天津艾努愛世医薬有限公司 / Excluded Number of companies 0 / Company name Not disclosed
Material subsequent eventsNo applicable matters.
Depreciation and amortization¥4,588 million
Issued Shares at Period-End70,251,484
Treasury Shares at Period-End2,898,434
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2021年4月1日〜2022年3月31日 |
| Net Sales | ¥137,484 million (YoY +12.8%) |
| Operating profit | ¥32,948 million (YoY +21.1%) |
| Ordinary income | ¥33,301 million (YoY +20.6%) |
| Profit attributable to owners of the parent | ¥24,986 million (YoY +27.9%) |
| Net income per share | 370.97円 |
| Operating Margin | 24.0% |
| Equity ratio | End of the current fiscal period 82.1% / End of previous period 79.4% |
| Total assets | ¥219,943 million |
| Net assets | ¥180,886 million |
| Cash flows from operating activities | ¥21,316 million |
| Cash flows from investing activities | ¥-10,037 million |
| Cash flows from financing activities | ¥-8,407 million |
| Cash and cash equivalents at end of period | ¥60,566 million |
| Full-year earnings forecast | Net Sales ¥134,000 million (YoY -2.5%) / Operating profit ¥27,000 million (YoY -18.1%) / Ordinary income ¥27,500 million (YoY -17.4%) / Net income ¥21,500 million (YoY -14.0%) |
| Annual Dividend Forecast | ¥110 → ¥112（+1.8%） |
| Payout ratio | 29.7%（2023年3月期予想35.1%） |
| Segment revenue | Pharmaceuticals Business ¥120,650 million, Functional Foods Business ¥16,834 million |
| Segment profit | Pharmaceuticals Business ¥32,244 million, Functional Foods Business ¥529 million |
| Regional sales | ¥94,367 million, ¥29,989 million, ¥29,982 million, ¥13,128 million, ¥137,484 million |
| Depreciation and amortization | ¥4,588 million |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New Number of companies 1 / Company name 天津艾努愛世医薬有限公司 / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | No applicable matters. |
| Issued Shares at Period-End | 70,251,484 |
| Treasury Shares at Period-End | 2,898,434 |
Items this document does not state (9)
Revision to Earnings ForecastShareholder Return PolicyOrders received and order backlogImpairment lossBreakdown of extraordinary income (loss)Disclosure regarding the going concern assumptionAvailability of Supplementary Financial Results MaterialsAvailability of Financial Results BriefingFactors Behind Changes in Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.業績の増減要因は記載されていない。業績予想については、現在入手している情報と合理的と判断する一定の前提に基づくとしている。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.